Type I interferon pathway in pediatric systemic lupus erythematosus

Area of Science:

• Immunology
• Pediatric Rheumatology

Background:

• Type I interferon (IFN-I) signaling is a known factor in systemic lupus erythematosus (SLE).
• Its specific role in pediatric-onset SLE requires further elucidation.
• This review focuses on recent discoveries concerning IFN-I in pediatric SLE.

Purpose of the Study:

• To provide an overview of novel discoveries on IFN-I signaling in pediatric-onset SLE.
• To highlight the significance of IFN-I in the pathogenesis of pediatric SLE.
• To discuss potential diagnostic markers and therapeutic strategies.

Main Methods:

• Literature search conducted on PubMed.
• Keywords used: "pediatric systemic lupus erythematosus" and "type I interferon".

Main Results:

• Increased IFN-I signaling in pediatric SLE is linked to plasmacytoid dendritic cells and specific signaling pathways (e.g., cGAS-STING, TLR4/9).
• Neutrophil extracellular traps and oxidative DNA damage contribute to IFN-I production.
• Genetic variants in IFN-I-related genes are associated with SLE susceptibility in children.
• Type I interferonopathies can mimic SLE and offer insights into SLE pathogenesis.
• IFN-I activation markers (gene expression, serum IFN-α2, CD169, galectin-9) are crucial for diagnosis and stratification.
• Anti-IFN therapies show promise, but pediatric efficacy needs more study; JAK inhibitors are an option for severe cases.

Conclusions:

• The IFN-I pathway plays a significant role in pediatric SLE.
• Further understanding can lead to improved diagnostic markers and targeted therapies.
• This knowledge is essential for enhancing patient care and outcomes in pediatric SLE.